July 19th 2023
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
July 12th 2023
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
July 5th 2023
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
June 28th 2023
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
June 21st 2023
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
January 31st 2023
Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.
October 26th 2022
Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.
September 24th 2021
Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.
September 9th 2021
Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.
September 2nd 2021
Stacey A. Cohen, MD, discusses tailoring treatment approaches to individual subtypes in colorectal cancer.
August 4th 2021
Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.
August 2nd 2021
Stacey A. Cohen, MD, discusses the clinical implications of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.
July 21st 2021
Stacey A. Cohen MD, discusses the preliminary results of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.